Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Multiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in the bone marrow. Although its treatment consists of the administration of combined therapy regimens mainly based on immunomodulators and proteosome inhibitors, MM remains...
Main Authors: | Federico Riccardi, Carmela Tangredi, Michele Dal Bo, Giuseppe Toffoli |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1370854/full |
Similar Items
-
Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
by: Arzu Cengiz, et al.
Published: (2018-08-01) -
THE NEW DIAGNOSTIC FEATURES OF CD138 (SYNDECAN-1) IN MULTIPLE MYELOMA
by: A. F. Karamysheva
Published: (2015-12-01) -
Multidimensional role of adapalene in regulating cell death in multiple myeloma
by: Xinya Cao, et al.
Published: (2024-08-01) -
Comparison of the IHC markers CD138 and CD43 in oral leukoplakia: An original research
by: Anitha Akkaloori, et al.
Published: (2023-01-01) -
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)